Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7119744 | 0.83 | KDR (0.62) | KDRCYP1A2CYP3A4CYP2D6ALOX15 | |
| SCHEMBL6542710 | 0.82 | KDR (0.62) | KDRALDH1A1 | |
| SCHEMBL7996741 | 0.79 | KDR (0.49) | KDRMAPTALDH1A1PDE5ACYP1A2 | |
| SCHEMBL1715953 | 0.76 | KDM4C (0.61) | ALDH1A1HSD17B10TSHRKDM4EGLA | |
| SCHEMBL1465529 | 0.76 | KDR (0.46) | KDRMAPTALDH1A1PDE5AHDAC3 | |
| SCHEMBL18070888 | 0.76 | AGTR1 (0.61) | KDRAGTR1AGTR2MAPTALDH1A1 | |
| SCHEMBL429092 | 0.75 | KDR (0.78) | KDR | |
| SCHEMBL3151267 | 0.73 | KDR (0.64) | KDRALDH1A1KDM4E | |
| SCHEMBL1714816 | 0.73 | ALDH1A1 (0.71) | KDRALDH1A1ALOX15HSD17B10TSHR | |
| SCHEMBL3712006 | 0.72 | RPS6KB1 (0.63) | KDRAGTR1AGTR2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071165-A1 | Aza- and polyazanthranyl amides and their use as medicaments | NOVARTIS AG (CH) | 2011-03-24 | — | — | US | claimed |
| US-20060287339-A1 | Aza- and polyazanthranyl amides and their use as medicaments | SEIDELMANN DIETER | 2006-12-21 | — | — | US | claimed |
| US-20040224968-A1 | Aza-and polyazanthranyl amides and their use as medicaments | NOVARTIS AG (CH) | 2004-11-11 | — | — | US | claimed |
| US-20110071165-A1 | Aza- and polyazanthranyl amides and their use as medicaments | NOVARTIS AG (CH) | 2011-03-24 | — | — | US | disclosed |
| US-20060287339-A1 | Aza- and polyazanthranyl amides and their use as medicaments | SEIDELMANN DIETER | 2006-12-21 | — | — | US | disclosed |
| US-20040224968-A1 | Aza-and polyazanthranyl amides and their use as medicaments | NOVARTIS AG (CH) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287339-A1 | Aza- and polyazanthranyl amides and their use as medicaments | VEGFA, AZI2, TPMT | KDR 8/4885AGTR1 1342/4885AGTR2 876/4885 |
| US-20040224968-A1 | Aza-and polyazanthranyl amides and their use as medicaments | AZI2, VEGFA, TPMT | KDR 19/4885AGTR1 1691/4885AGTR2 1013/4885 |
| US-20110071165-A1 | Aza- and polyazanthranyl amides and their use as medicaments | VEGFA, AZI2, TPMT | KDR 8/4885AGTR1 1342/4885AGTR2 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.